Hematology-American Society of Hematology Education Program

Article	Citations
Managing toxicities of Bruton tyrosine kinase inhibitors	92
Therapeutic development and current uses of BCL-2 inhibition	74
Platelet transfusion refractoriness: how do I diagnose and manage?	49
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors	45
Preventing infections in children and adults with asplenia	44
Monoclonal gammopathies of clinical significance	42
Updates in infection risk and management in acute leukemia	40
Bispecifics, trispecifics, and other novel immune treatments in myeloma	40
Gene therapy for hemophilia	40
Therapy for lower-risk MDS	34
Management of AL amyloidosis in 2020	34
Updates in chronic graft-versus-host disease	34
Dyskeratosis congenita and telomere biology disorders	34
Next-generation cell therapies: the emerging role of CAR-NK cells	32
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	30
Inferior vena cava filters: a framework for evidence-based use	29
Does ABO and RhD matching matter for platelet transfusion?	28
Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics	27
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry	26
Advances in the management of α-thalassemia major: reasons to be optimistic	26
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia	26
Future of CAR T cells in multiple myeloma	25
Outpatient transfusions for myelodysplastic syndromes	24
Management of Waldenström macroglobulinemia in 2020	24
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review	24

Modern management of Fanconi anemia	24
Approach to the patient with suspected hypereosinophilic syndrome	24
Have we reached a molecular era in myelodysplastic syndromes?	23
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management	23
Combining antiplatelet and anticoagulant therapy in cardiovascular disease	22
Allogeneic hematopoietic cell transplantation for older patients	22
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic di	22
What to use to treat AML: the role of emerging therapies	21
Antibodies and bispecifics for multiple myeloma: effective effector therapy	21
Women and bleeding disorders: diagnostic challenges	20
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?	20
Gene therapy for sickle cell disease: where we are now?	20
High-risk multiple myeloma: how to treat at diagnosis and relapse?	20
Indications for transfusion in the management of sickle cell disease	20
Optimizing the management of chronic pain in sickle cell disease	19
Identifying potential germline variants from sequencing hematopoietic malignancies	19
Epidemiology and treatment of priapism in sickle cell disease	19
Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management	18
Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes	18
How to avoid the problem of erythrocyte alloimmunization in sickle cell disease	18
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?	18
Management of heavy menstrual bleeding on anticoagulation	18
Mechanisms of somatic transformation in inherited bone marrow failure syndromes	17
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)	17
Does aspirin prevent venous thromboembolism?	17
How do we sequence therapy for marginal zone lymphomas?	17
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms	17
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	17
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop	17
Blast and accelerated phase CML: room for improvement	16
Cellular therapy for multiple myeloma: what's now and what's next	16
How to recognize and manage COVID-19-associated coagulopathy	16
Double-hit lymphoma: optimizing therapy	16
Hematology 2022—what is complete HLA match in 2022?	15
Treatment of Richter's syndrome	15
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings	15
Hemophilia gene therapy: ushering in a new treatment paradigm?	15
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban	15
When does a PNH clone have clinical significance?	15
Transformed lymphoma: what should I do now?	15
Chemotherapy-free frontline therapy for CLL: is it worth it?	15
Challenges in chronic transfusion for patients with thalassemia	14
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	14
In 2022, which is preferred: haploidentical or cord transplant?	14
Extrahematopoietic manifestations of the short telomere syndromes	14
How to manage CML patients with comorbidities	14
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	13
Diamond-Blackfan anemia	13
Molecular prognostication in Ph-negative MPNs in 2022	13
Genomics of MPN progression	13

Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP	13
Achieving MRD negativity in AML: how important is this and how do we get there?	13
Relapsed ALL: CAR T vs transplant vs novel therapies	13
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs	13
Direct oral anticoagulant (DOAC) interference in hemostasis assays	13
Global look at nutritional and functional iron deficiency in infancy	13
Sequencing multiple myeloma therapies with and after antibody therapies	12
Sequencing therapy in relapsed DLBCL	12
Heparin-induced thrombocytopenia and cardiovascular surgery	12
How to evaluate and treat the spectrum of TMA syndromes in pregnancy	12
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?	12
Inherited microcytic anemias	12
COVID-19 and thrombosis: searching for evidence	12
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life	11
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	11
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency	11
Unexplained arterial thrombosis: approach to diagnosis and treatment	11
Warm autoimmune hemolytic anemia and the best treatment strategies	11
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas	11
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation	11
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	11
How immunodeficiency can lead to malignancy	10
When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?	10
Transplant for TP53-mutated MDS and AML: because we can or because we should?	10
Management of hemolytic transfusion reactions	10
Management of TKI-resistant chronic phase CML	10
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies	10
Lower risk but high risk	10
Clinical screening for Ph-like ALL and the developing role of TKIs	10
Transplantation in CML in the TKI era: who, when, and how?	10
AL amyloidosis: untangling new therapies	10
Optimizing management of acute leukemia in community centers and when to refer	9
How well do platelets prevent bleeding?	9
Noninfectious lung complications of hematopoietic cell transplantation	9
Incorporating gonadal health counseling into pediatric care of sickle cell patients	9
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy	9
Evidence-Based Minireview: Treatment of relapsed chronic lymphocytic leukemia after venetoclax	9
Lifelong TKI therapy: how to manage cardiovascular and other risks	9
Rebalanced hemostasis in liver disease: a misunderstood coagulopathy	9
CAR T cells vs allogeneic HSCT for poor-risk ALL	9
Novel targets in aggressive lymphoma	9
How do I sequence therapy for follicular lymphoma?	9
CNS prophylaxis in aggressive B-cell lymphoma	9
Minimal residual disease in multiple myeloma: why, when, where	9
How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia	9
A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact	8
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?	8
Diagnosis and clinical management of red cell membrane disorders	8
Approaches for relapsed CLL after chemotherapy-free frontline regimens	8
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents	8
The clinical and laboratory evaluation of patients with suspected hypocellular marrow failure	8
Passive immune therapies: another tool against COVID-19	8
Bispecific antibody therapies	8
Long-term prophylaxis: what are our options and how to define success?	8
Role of venous stenting for venous thromboembolism	8
Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?	8
Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?	8
Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond	7
What else do I need to worry about when treating graft-versus-host disease?	7
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma	7
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	7
Targeting inflammation in lower-risk MDS	7
Treatment of CML in pregnancy	7
Genetics of severe congenital neutropenia as a gateway to personalized therapy	7
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	7
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	7
Fitness and frailty in myeloma	7
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	7
The consultant's guide to smoldering multiple myeloma	7
When I treat a patient with acute pulmonary embolism at home	7
Current use of bispecific antibodies to treat multiple myeloma	7
CAR T cells for other pediatric non–B-cell hematologic malignancies	7
New approaches to tackle cytopenic myelofibrosis	7
Frontline treatment in CLL: the case for time-limited treatment	7
Platelet components and bacterial contamination: hospital perspective 2022	7
Leukemogenesis in infants and young children with trisomy 21	7
Risk stratifying MDS in the time of precision medicine	7
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	7
Harnessing lymphoma epigenetics to improve therapies (article not eligible for CME credit)	6
Minimizing cardiac toxicity in children with acute myeloid leukemia	6

Thrombocytopenia and liver disease: pathophysiology and periprocedural management	6
Strategies for aggressive T-cell lymphoma: divide and conquer	6
Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation	6
Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?	6
Gene therapy for sickle cell disease	6
Cold AIHA and the best treatment strategies	6
What have we learned about the patient's experience of von Willebrand disease? A focus on women	6
Managing therapy-associated neurotoxicity in children with ALL	6
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	6
Expanding the platelet inventory to mitigate the impact of severe shortages	6
Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?	6
Current use of CAR T cells to treat multiple myeloma	6
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	6
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	6
Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody–based treatment?	6
Applied genomics in MPN presentation	6
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map	6
Evidence-Based Minireview: Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism	6
New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT)	6
Treatment of older adult or frail patients with multiple myeloma	6
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?	6
Managing side effects: guidance for use of immunotherapies in multiple myeloma	6
Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?	6
Recognizing, defining, and managing CAR-T hematologic toxicities	6
Transplant in AML with measurable residual disease: proceed or defer?	6
Psychosocial and financial issues after hematopoietic cell transplantation	5
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	5
Perioperative hemostasis for patients with hemophilia	5
Management of marginal zone lymphomas	5
Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation	5
Selecting initial therapy in CLL	5
Resistance mutations in CML and how we approach them	5
Novel immunotherapies in the treatment of AML: is there hope?	5
Optimizing management of sickle cell disease in patients undergoing surgery	5
Diagnosis and clinical management of enzymopathies	5
Follicular lymphoma: is there an optimal way to define risk?	5
Special considerations in GI bleeding in VWD patients	5
How to diagnose and manage antiphospholipid syndrome	5
Does MRD have a role in the management of iNHL?	5
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	5
Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease	5
Evidence-Based Minireview: What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?	5
Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism	5
Ph+ ALL in 2022: is there an optimal approach?	5
Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation	5
Optimizing outcomes in secondary AML	5
Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy	5
What factors guide treatment selection in mycosis fungoides and Sezary syndrome?	5